KIORA PHARMACEUTICALS, INC. Foreign Currency Transaction Gain (Loss), before Tax
KIORA PHARMACEUTICALS, INC. (KPRX) reported Foreign Currency Transaction Gain (Loss), before Tax of -$14.50 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-23.
Discontinued › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2023-03-23
- KIORA PHARMACEUTICALS, INC. foreign currency transaction gain (loss), before tax for fiscal 2022 was -$14.50K.
- KIORA PHARMACEUTICALS, INC. foreign currency transaction gain (loss), before tax for fiscal 2021 was $0.00.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|
| 2022-12-31 | -$14.50K 10-K · filed 2023-03-23 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |